Editorial Policy

This page describes how Delta Dossier produces what it publishes. It is short because the rules are short.

How we assess this niche

We cover alternative cannabinoids — a category where the lab sheet and the law decide almost everything — so our method starts there. For every brand we review, we check the same four things in the same order: COA accessibility (can a buyer find the certificate of analysis for a specific batch without contacting support); panel scope (what the lab actually screened for — potency alone, or residual solvents and byproducts, which matter for converted cannabinoids); catalog honesty (whether products are labeled and marketed as what they are); and legal posture (how the brand handles the state patchwork and the moving federal definition). Facts we cannot verify ourselves are attributed and hedged — “the company says”, “per public reporting”, “as of this writing”. We do not invent statistics, quotes, or test results, and we do not present a vendor's numbers as our own measurements.

No medical claims

Nothing on this site is medical advice, and no product we cover is presented as diagnosing, treating, curing, or preventing anything. Effects are described only as what a product is marketed for or what users report. We publish for adults 21 and over, and every availability discussion comes with the same instruction: check your state's laws before you buy.

What scores mean

Scores are out of 10 and are editorial judgments of the brand as a whole — the paperwork, the products, the pricing, and how honestly it all is sold. As a practical guide: below 5 means we would not buy it; 5–7 means a competent operation with real caveats; 8 and above means a brand that leads its category — and still lists its cons, because every brand has them. In a category with this much testing variability and regulatory weather, perfect scores would be dishonest, and we don't give them. No score is for sale.

Disclosure

Delta Dossier is commercially supported and may earn affiliate commissions or advertising revenue from links. Any paid or affiliate content carries a disclosure notice at the top of the post, and paid links are marked rel="sponsored" in the page's code. Sponsors get clearly labelled space; they do not get editorial control, and they do not get conclusions.

Bylines

Delta Dossier publishes under house bylines maintained by the editorial team. Reviews run under the byline of our editor, Casey Marlow — a disclosed house pen name, in the tradition of publications that write under a house identity — and news runs as “Staff, Delta Dossier”. The pen name is the accountable editorial identity for everything published under it. We do not fabricate journalist biographies or credentials.

Corrections

We correct errors of fact quickly and visibly — and in this niche that includes legal status, which can change between our publishing and your reading. If you spot an error — a spec, a date, a state rule that has moved — use the contact page and flag it as a correction. We aim to act on corrections within a few business days.